Top Four Trials from TCT 2024: EARLY TAVR, TRISCEND II for Tricuspid Regurgitation, ECLIPSE on orbital atherectomy, and CLEAR SYNERGY (OASIS 9) & colchicine treatment
Eagle's Eye View: Your Weekly CV Update From ACC.org
00:00
Key Trials from TCT 2024: Impacts on Cardiovascular Practice
This chapter highlights four pivotal clinical trials from the TCT meeting that have the potential to transform cardiovascular practice. It reviews studies on TAVR for asymptomatic aortic stenosis, valve technology for tricuspid regurgitation, orbital atherectomy vs. PCI, and the effects of colchicine in post-PCI patients.
Transcript
Play full episode
